Puma Biotechnology

Aging Populations Will Boost Personalized Oncology While Regulatory Risks Persist

AnalystHighTarget

Not Invested

Community Contributor

Published

29 May 25

n/a

AnalystHighTarget's Fair Value

n/a

81.0%

4.9%

81.0%

4.9%

You can edit this narrative until May 29 9:10 PM. Then, changes will post as Updates.

Author's Valuation

US$424.0% overvalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$4

24.0% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

0.08%

Biotech revenue growth rate

8.15%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.25%

Calculation

US$6.77m

Earnings '28

37.16x

PE Ratio '28

US$251.41m

Market Cap '28

US$251.41m

Market Cap '28

51.46m

No. shares '28

US$4.89

Share Price '28

US$4.89 Share Price '28

Discounted to 2025 @ 7.21% p.a.

US$3.96

Fair Value '25